Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fragile X syndrome
Biotech
Harmony's pivotal trial flops as placebo response causes discord
Two years after picking up ZYN002 despite a midphase flop, the biotech has reported that a registrational trial missed its primary endpoint.
Nick Paul Taylor
Sep 24, 2025 9:35am
Servier supercharges neuro pipeline with $450M deal
Sep 8, 2025 2:30am
Stalicla pledges $270M for Novartis' failed fragile X asset
Jan 9, 2023 8:06am
Merck KGaA taps into Quris' stem cell-powered drug screening AI
Feb 14, 2022 10:15am
Ovid pens deal to offload twice-failed former lead program
Feb 8, 2022 9:10am
Quris launches with $9M for AI to predict drug success, safety
Oct 18, 2021 7:30am
